Location History:
- Del Mar, CA (US) (2011 - 2014)
- La Jolla, CA (US) (2019 - 2023)
Company Filing History:
Years Active: 2011-2023
Title: The Innovations of Palmer Taylor
Introduction
Palmer Taylor is a distinguished inventor based in La Jolla, California. He has made significant contributions to the field of pharmacology, particularly in developing antidotes for organophosphate poisoning. With a total of eight patents to his name, Taylor's work has had a profound impact on medical treatments and safety.
Latest Patents
Among his latest patents are "Centrally active and orally bioavailable uncharged bisoxime antidotes for organophosphate poisoning and methods for making and using them." This invention focuses on uncharged bis-oxime antidotes that can cross the blood-brain barrier to catalyze the hydrolysis of organophosphate-inhibited human acetylcholinesterase in the central nervous system. Another notable patent is "Centrally active and orally bioavailable antidotes for organophosphate exposure and methods for making and using them." This invention provides nucleophilic hydroxyimino-acetamido alkylamine antidotes designed to fit within the active center of acetylcholinesterase, enhancing their effectiveness in treating organophosphate exposure.
Career Highlights
Palmer Taylor has had a remarkable career, working at prestigious institutions such as the University of California and The Scripps Research Institute. His research has focused on developing innovative solutions to complex medical challenges, particularly in the area of neuropharmacology.
Collaborations
Throughout his career, Taylor has collaborated with notable scientists, including Zoran Radic and Valery Fokin. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.
Conclusion
Palmer Taylor's contributions to the field of pharmacology and his innovative patents have significantly advanced the treatment of organophosphate poisoning. His work continues to influence medical practices and improve patient outcomes.